Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GOPAL R KUNTA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1043209950
CMS profile
137735
Location
CLERMONT, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$6,602.01

124 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,371.46 118
Consulting Fee $2,847.50 2
Education $216.39 2
Long term medical supply or device loan $166.66 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GOPAL R KUNTA

NPI 1043209950 · CMS profile ID 137735

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CLERMONT, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043209950?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GOPAL R KUNTA, NPI 1043209950, CMS profile ID 137735. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043209950?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). GOPAL R KUNTA, NPI 1043209950, CMS profile ID 137735. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043209950?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
GOPAL R KUNTA, NPI 1043209950, CMS profile ID 137735, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1043209950?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

124 matching records · $6,602.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 124 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–124 of 124.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Puma Biotechnology, Inc. $23.7002/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059057919 CMS
GENZYME CORPORATION $28.5402/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049946555 CMS
SOBI, INC $20.8102/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038079581 CMS
Karyopharm Therapeutics Inc. $19.1602/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056900659 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $83.3302/15/2023 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993435283 CMS
Tolmar, Inc. $16.6702/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056970510 CMS
Janssen Biotech, Inc. $2.1502/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988074679 CMS
Coherus Biosciences Inc. $16.4402/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060237353 CMS
Novartis Pharmaceuticals Corporation $25.0302/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992276205 CMS
Exelixis Inc. $14.1302/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044517627 CMS
Grifols USA, LLC $15.4601/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011789113 CMS
Amgen Inc. $15.9101/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019918683 CMS
GlaxoSmithKline, LLC. $25.6101/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002579205 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.4401/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000508747 CMS
Janssen Biotech, Inc. $22.4501/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988074689 CMS
Lilly USA, LLC $116.4001/17/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031550191 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $83.3301/14/2023 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993435281 CMS
Coherus Biosciences Inc. $26.3101/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060237337 CMS
PFIZER INC. $20.5301/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050668485 CMS
BeiGene USA, Inc. $16.4401/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051195063 CMS
Incyte Corporation $13.2201/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044432323 CMS
PFIZER INC. $7.0501/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049208881 CMS
Novartis Pharmaceuticals Corporation $24.9801/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992276201 CMS
Merck Sharp & Dohme LLC $24.9801/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048582015 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14,821.91 161
PY2020 $4,044.95 152
PY2021 $5,013.18 149
PY2022 $3,325.92 102
PY2023 $6,602.01 124
PY2024 $4,811.11 106
PY2025 $3,453.22 96

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $588.40 2
PY2025 Principal investigator $646,271.88 133
PY2024 Recipient $930.72 4
PY2024 Principal investigator $395,431.88 68
PY2023 Recipient $924.11 2
PY2023 Principal investigator $258,308.13 9
PY2022 Principal investigator $29,810.03 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

135 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $27,658.05 12/31/2025 Non-covered Recipient Entity
Clermont Oncology Center
KEYMAKER-U01 Substudy 01F# A Phase 1b,2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC With KRAS G12C Mutations No dispute reported 06/30/2026 1232925185
Principal investigator 1 Merck Sharp & Dohme LLC $5,737.59 12/31/2025 Non-covered Recipient Entity
Clermont Oncology Center
KEYMAKER-U01 Substudy 01J# A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC With KRAS G12C Mutations No dispute reported 06/30/2026 1232925257
Principal investigator 1 Merck Sharp & Dohme LLC $33,682.50 12/31/2025 Non-covered Recipient Entity
Clermont Oncology Center
KEYMAKER-U01 Substudy 01J# A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC With KRAS G12C Mutations No dispute reported 06/30/2026 1232925303
Principal investigator 1 Merck Sharp & Dohme LLC $4,905.00 12/31/2025 Non-covered Recipient Entity
Clermont Oncology Center
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatm No dispute reported 06/30/2026 1232928676
Principal investigator 1 BioNTech SE $21,000.00 12/19/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327 No dispute reported 06/30/2026 1249018374
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $425.00 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184274941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,452.16 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $578.10 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $483.63 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $425.00 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $483.63 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $578.10 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,452.16 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $483.63 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $578.10 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,452.16 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $425.00 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $483.63 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,452.16 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $578.10 12/12/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184274969
Principal investigator 1 BioNTech SE $1,800.00 12/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327 No dispute reported 06/30/2026 1249018360
Principal investigator 1 BioNTech SE $2,308.00 12/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327 No dispute reported 06/30/2026 1249018362
Principal investigator 1 BioNTech SE $1,500.00 12/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327 No dispute reported 06/30/2026 1249018364
Principal investigator 1 BioNTech SE $2,300.00 12/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327 No dispute reported 06/30/2026 1249018366
Principal investigator 1 BioNTech SE $225.00 12/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327 No dispute reported 06/30/2026 1249018368
Principal investigator 1 BioNTech SE $3,125.00 12/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327 No dispute reported 06/30/2026 1249018370
Principal investigator 1 BioNTech SE $1,300.00 12/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327 No dispute reported 06/30/2026 1249018372
Principal investigator 1 BioNTech SE $2,300.00 12/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327 No dispute reported 06/30/2026 1249018472
Principal investigator 1 BioNTech SE $225.00 12/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327 No dispute reported 06/30/2026 1249018474
Principal investigator 1 BioNTech SE $1,500.00 12/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327 No dispute reported 06/30/2026 1249018476
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,996.00 12/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184274524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $850.00 12/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184274526
Principal investigator 1 Hexal AG $150.00 12/08/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348566
Principal investigator 1 Hexal AG $3,544.00 12/08/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348568
Principal investigator 1 Hexal AG $213.00 12/08/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348570
Principal investigator 1 Hexal AG $450.00 12/08/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348572
Principal investigator 1 Hexal AG $450.00 12/08/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348580
Principal investigator 1 Hexal AG $450.00 12/08/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348582
Principal investigator 1 Hexal AG $450.00 12/05/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348562
Principal investigator 1 BioNTech SE $2,300.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327-03 No dispute reported 06/30/2026 1249018376
Principal investigator 1 BioNTech SE $225.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327-03 No dispute reported 06/30/2026 1249018378
Principal investigator 1 BioNTech SE $1,300.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327-03 No dispute reported 06/30/2026 1249018380
Principal investigator 1 BioNTech SE $895.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327-03 No dispute reported 06/30/2026 1249018382
Principal investigator 1 BioNTech SE $225.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327-03 No dispute reported 06/30/2026 1249018478
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $906.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,603.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,584.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $484.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $512.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $683.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,313.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $425.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,973.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,068.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $512.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $683.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,313.00 12/04/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,722.15 11/27/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184265849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,060.45 11/27/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184265851
Principal investigator 1 BioNTech SE $92.00 11/01/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327-03 No dispute reported 06/30/2026 1249018398
Principal investigator 1 BioNTech SE $92.00 11/01/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
BNT327-03 No dispute reported 06/30/2026 1249018484
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,060.45 10/29/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184254301
Principal investigator 1 Merck Sharp & Dohme LLC $57,960.00 10/27/2025 Non-covered Recipient Entity
Clermont Oncology Center
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232932281
Principal investigator 1 Hexal AG $180.00 10/23/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348624
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,722.15 10/03/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184245339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,060.45 09/29/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184243859
Principal investigator 1 SANOFI US SERVICES INC. $2,963.00 09/24/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098538
Principal investigator 1 SANOFI US SERVICES INC. $450.00 09/24/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098543
Principal investigator 1 SANOFI US SERVICES INC. $3,563.00 09/24/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098548
Principal investigator 1 SANOFI US SERVICES INC. $2,963.00 09/24/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098554
Principal investigator 1 SANOFI US SERVICES INC. $2,963.00 09/24/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098562
Principal investigator 1 SANOFI US SERVICES INC. $1,745.00 09/24/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098569
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 09/24/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098574
Principal investigator 1 SANOFI US SERVICES INC. $2,980.00 09/24/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098580
Principal investigator 1 SANOFI US SERVICES INC. $3,589.00 09/24/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098585
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $23,000.00 09/16/2025 Non-covered Recipient Entity
CLERMONT ONCOLOGY CENTER LLC
ALI-4201 No dispute reported 06/30/2026 1251753712
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098414
Principal investigator 1 SANOFI US SERVICES INC. $14,000.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098419
Principal investigator 1 SANOFI US SERVICES INC. $3,389.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098425
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098433
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098443
Principal investigator 1 SANOFI US SERVICES INC. $2,750.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098449
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098455
Principal investigator 1 SANOFI US SERVICES INC. $2,980.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098461
Principal investigator 1 SANOFI US SERVICES INC. $1,745.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098467
Principal investigator 1 SANOFI US SERVICES INC. $450.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098472
Principal investigator 1 SANOFI US SERVICES INC. $2,963.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098480
Principal investigator 1 SANOFI US SERVICES INC. $2,963.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098487
Principal investigator 1 SANOFI US SERVICES INC. $1,300.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098493
Principal investigator 1 SANOFI US SERVICES INC. $450.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098500
Principal investigator 1 SANOFI US SERVICES INC. $3,589.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098505
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098511
Principal investigator 1 SANOFI US SERVICES INC. $3,563.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098526
Principal investigator 1 SANOFI US SERVICES INC. $2,963.00 09/12/2025 Non-covered Recipient Entity
Alpha Clinical Research Centers Llc
A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors No dispute reported 06/30/2026 1226098533
Principal investigator 1 Hexal AG $450.00 09/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348618
Principal investigator 1 Hexal AG $2,554.23 09/03/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348606
Principal investigator 1 Hexal AG $1,320.36 09/03/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348608
Principal investigator 1 Hexal AG $4,112.00 09/03/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,060.45 09/01/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184233340
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,722.15 09/01/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184233342
Principal investigator 1 Merck Sharp & Dohme LLC $46,548.48 08/31/2025 Non-covered Recipient Entity
Clermont Oncology Center
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatm No dispute reported 06/30/2026 1232928678
Principal investigator 1 Hexal AG $1,320.36 08/18/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348614
Principal investigator 1 Hexal AG $180.00 08/18/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348616
Principal investigator 1 Hexal AG $13,252.24 08/13/2025 Non-covered Recipient Entity
MID-FLORIDA HEMATOLOGY ONCOLOGY
CGME751A12101 No dispute reported 06/30/2026 1186348826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,060.45 07/28/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184220558
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,921.90 07/28/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184220560
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,060.45 07/28/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184220562
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,722.15 07/28/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184220564
Principal investigator 1 Hexal AG $1,350.28 07/09/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
CGME751A12101 No dispute reported 06/30/2026 1186348612
Principal investigator 1 Hexal AG $21,700.40 06/19/2025 Non-covered Recipient Entity
CLERMONT ONCOLOGY CENTER
CGME751A12101 No dispute reported 06/30/2026 1186348492
Recipient Regeneron Pharmaceuticals, Inc. $364.58 05/31/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184119277
Principal investigator 1 Hexal AG $13,252.24 04/30/2025 Non-covered Recipient Entity
CLERMONT ONCOLOGY CENTER
CGME751A12101 No dispute reported 06/30/2026 1186348494
Principal investigator 1 Hexal AG $117.68 04/30/2025 Non-covered Recipient Entity
CLERMONT ONCOLOGY CENTER
CGME751A12101 No dispute reported 06/30/2026 1186348496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,060.45 04/28/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184190525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,259.35 04/28/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184190527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,722.15 04/28/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184190529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,722.15 04/28/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184190533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,060.45 04/28/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184190535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,722.15 04/28/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184190537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,459.95 04/01/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184180924
Recipient Regeneron Pharmaceuticals, Inc. $223.82 03/25/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184119275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,193.55 03/25/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184178880
Principal investigator 1 Hexal AG $13,252.24 03/21/2025 Non-covered Recipient Entity
CLERMONT ONCOLOGY CENTER
CGME751A12101 No dispute reported 06/30/2026 1186348502
Principal investigator 1 Hexal AG $21,700.40 03/20/2025 Non-covered Recipient Entity
CLERMONT ONCOLOGY CENTER
CGME751A12101 No dispute reported 06/30/2026 1186348498
Principal investigator 1 Hexal AG $30.64 03/20/2025 Non-covered Recipient Entity
CLERMONT ONCOLOGY CENTER
CGME751A12101 No dispute reported 06/30/2026 1186348500
Principal investigator 1 Hexal AG $13,252.24 03/20/2025 Non-covered Recipient Entity
CLERMONT ONCOLOGY CENTER
CGME751A12101 No dispute reported 06/30/2026 1186348504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,856.95 03/13/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184173822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,856.95 03/13/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184173824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,341.65 03/11/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184170904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $578.10 02/20/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184154744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,452.16 02/20/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184154746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $483.63 02/20/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184154748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,284.00 01/21/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184149046
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,454.45 01/17/2025 Non-covered Recipient Entity
ALPHA CLINICAL RESEARCH CENTERS LLC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184148077
Principal investigator 1 BioNTech SE $98.10 01/01/2025 Non-covered Recipient Entity
Clermont Oncology Center
BNT327-03 No dispute reported 06/30/2026 1249017346